Clinical TrialJul 6, 2026, 07:01 AM
Belite Bio to Present Phase 3 DRAGON Study Results for Tinlarebant
AI Summary
Belite Bio, Inc. announced it will present topline results from its Phase 3 DRAGON study of Tinlarebant for adolescent Stargardt’s Disease at two major scientific symposia in July 2026. The presentations will occur at the 63rd Annual Symposium of the International Society for Clinical Electrophysiology of Vision (ISCEV) in Sydney, Australia, and the American Society of Retina Specialists (ASRS) 2026 Annual Meeting in Montréal, Canada. Tinlarebant, an oral therapy for degenerative retinal diseases, has previously received multiple designations including Breakthrough Therapy and Orphan Drug.
Key Highlights
- Belite Bio to present topline Phase 3 DRAGON study results for Tinlarebant.
- Data will be presented at the 63rd Annual ISCEV Symposium from July 6-11, 2026.
- Results also to be presented at the ASRS 2026 Annual Meeting from July 15-18, 2026.
- Presentations focus on Tinlarebant for adolescent Stargardt’s Disease.
- Tinlarebant has Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug Designations.
- The Phase 3 DRAGON trial previously met its primary endpoint.
Price Impact
More from BLTE